CTD²: Cancer Target Discovery and Development

CTD2 bridges the gap between the enormous volumes of data generated by genomic characterization studies and the ability to use these data for the development of human cancer therapeutics. It specializes in computational and functional genomics approaches critical for translating next-generation sequencing data, as well as high-throughput and high content small molecule and genetic screens.

Banner for CTD squared program. Links to CTD squared program page
Last updated: January 12, 2018

News & Publications

previousnext
Heat map visualizing functional patterns in large scale data sets. These patterns are brought into biological context by data mining.
CTD²
March 29, 2018

Purpose: Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide with high mortality and a lack of targeted therapies. To identify and prioritize druggable targets, we performed genome analysis together with genome-scale siRNA and oncology drug...

Graphical Abstract from Huang et al., 2018.
CTD²
March 26, 2018

Gene networks are rapidly growing in size and number, raising the question of which networks are most appropriate for particular applications. Here, we evaluate 21 human genome-wide interaction networks for their ability to recover 446 disease gene sets identified through literature curation,...

Histopathologic image illustrating well differentiated squamous cell carcinoma in the excisional biopsy specimen. Hematoxylin-eosin stain.
CTD²
March 13, 2018

Purpose: The WEE1 tyrosine kinase regulates G2/M transition and maintains genomic stability, particularly in p53-deficient tumors which require DNA repair after genotoxic therapy. There is a need to exploit the role of WEE1 inhibition in head and neck squamous cell carcinoma (...

Protein-protein interactions generated using Preppi (v1.0)
CTD²
,
TARGET
March 06, 2018

High-risk neuroblastomas show a paucity of recurrent somatic mutations at diagnosis. As a result, the molecular basis for this aggressive phenotype remains elusive. Recent progress in regulatory network analysis helped us elucidate disease-driving mechanisms downstream of genomic alterations,...

uHTS assay to discover MYC/NSD3 inhibitors
CTD²
March 01, 2018

Epigenetic modulators play critical roles in reprogramming of cellular functions, emerging as a new class of promising therapeutic targets. Nuclear receptor binding SET domain protein 3 (NSD3) is a member of the lysine methyltransferase family. Interestingly, the short isoform of NSD3 without...

O
O
O
O
O